Contrast Induced Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 μmol/L) increase in absolute SCr value after 48-72 hours contrast administration). Symptoms include tiredness, poor appetite, swelling in the feet and ankles, puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function, and congestive heart failure. Treatment includes electrolyte management.
The Contrast Induced Nephropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Contrast Induced Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects.
Key Targets in the Contrast Induced Nephropathy Pipeline Products Market
The key targets in the Contrast Induced Nephropathy pipeline products market are Thioredoxin, Atrial Natriuretic Peptide Receptor 1, and Complement C1s Subcomponent.
Contrast Induced Nephropathy Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Contrast Induced Nephropathy Pipeline Products Market
The key mechanisms of action in the Contrast Induced Nephropathy pipeline products market are Thioredoxin Activator, Atrial Natriuretic Peptide Receptor 1 Agonist, and Complement C1s Subcomponent Inhibitor.
Contrast Induced Nephropathy Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Contrast Induced Nephropathy Pipeline Products Market
The key routes of administration in the Contrast Induced Nephropathy pipeline products market are intravenous, inhalational, intradermal, intramuscular, ophthalmic, oral, parenteral, and subcutaneous.
Contrast Induced Nephropathy Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Contrast Induced Nephropathy Pipeline Products Market
The key molecule types in the Contrast Induced Nephropathy pipeline products market are small molecule, peptide, recombinant peptide, and recombinant protein.
Contrast Induced Nephropathy Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Contrast Induced Nephropathy Pipeline Products Market
The major companies in the Contrast Induced Nephropathy pipeline products market are Radikal Therapeutics Inc, Daiichi Sankyo Co Ltd, Pharming Group NV, and Saghmos Therapeutics Inc.
Contrast Induced Nephropathy Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Thioredoxin, Atrial Natriuretic Peptide Receptor 1, and Complement C1s Subcomponent |
Key mechanism of action | Thioredoxin Activator, Atrial Natriuretic Peptide Receptor 1 Agonist, and Complement C1s Subcomponent Inhibitor |
Key routes of administration | Intravenous, Inhalational, Intradermal, Intramuscular, Ophthalmic, Oral, Parenteral, and Subcutaneous |
Key molecule type | Small Molecule, Peptide, Recombinant Peptide, and Recombinant Protein |
Major companies | Radikal Therapeutics Inc, Daiichi Sankyo Co Ltd, Pharming Group NV, and Saghmos Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast-Induced Nephropathy (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Contrast Induced Nephropathy pipeline products market?
The key targets in the Contrast Induced Nephropathy pipeline products market are Thioredoxin, Atrial Natriuretic Peptide Receptor 1, and Complement C1s Subcomponent.
-
What are the key mechanisms of action in the Contrast Induced Nephropathy pipeline products market?
The key mechanisms of action in the Contrast Induced Nephropathy pipeline products market are Thioredoxin Activator, Atrial Natriuretic Peptide Receptor 1 Agonist, and Complement C1s Subcomponent Inhibitor.
-
What are the key routes of administration in the Contrast Induced Nephropathy pipeline products market?
The key routes of administration in the Contrast Induced Nephropathy pipeline products market are intravenous, inhalational, intradermal, intramuscular, ophthalmic, oral, parenteral, and subcutaneous.
-
What are the key molecule types in the Contrast Induced Nephropathy pipeline products market?
The key molecule types in the Contrast Induced Nephropathy pipeline products market are small molecule, peptide, recombinant peptide, and recombinant protein.
-
Which are the major companies in the Contrast Induced Nephropathy pipeline products market?
The major companies in the Contrast Induced Nephropathy pipeline products market are Radikal Therapeutics Inc, Daiichi Sankyo Co Ltd, Pharming Group NV, and Saghmos Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.